Afya Ltd announces R1500 million commercial notes issuance in two series
Afya Limited has announced the first issuance of book-entry commercial notes through its wholly owned subsidiary, Afya Participações S.A., via a private placement to Opea Securitizadora S.A. The aggregate principal amount of the Commercial Notes is R$1,500.0 million, divided into two series. The First Series is valued at R$500.0 million, set to mature on October 15, 2028, with an interest rate equal to the Brazilian daily interbank deposit rate (Depósito Interfinanceiro) plus a 0.70% spread per year. The Second Series is valued at R$1,000.0 million, maturing on October 15, 2030, and carries an interest rate equal to the Brazilian daily interbank deposit rate plus a 0.85% spread per year. The proceeds from the issuance are intended for general corporate purposes, including the early redemption of existing debentures, repurchase of Series A perpetual convertible preferred shares, and liability management. The Commercial Notes will be guaranteed by several Afya subsidiaries.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Afya Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251009687052) on October 09, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.